Skip to content

Study · Animal study (in vivo) · rat · 2002

4 results

The hypothalamic melanocortin system stimulates the hypothalamo-pituitary-adrenal axis in vitro and in vivo in male rats.

Dhillo WS, Small CJ, Seal LJ, Kim MS, Stanley SA, Murphy KG, Ghatei MA, Bloom SR

Neuroendocrinology1 Apr 2002Cited by 51 (Europe PMC)

PMID11979051 (opens in a new tab)DOI10.1159/000054712 (opens in a new tab)PepBankPUB-11979051
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In male rats, intraparaventricular NDP-MSH increased plasma ACTH 10 min after injection versus saline.

    In plain wordsIn male rats, NDP-MSH injected into the brain raised blood ACTH levels compared with saline.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    IncreasePlasma ACTH 10 min after injection
    Study

    ratn: not reported in source

    in vivo, male rats
    Comparator
    Saline
    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    Dose not stated · intraparaventricular nuclear injectionAs given in this study (rat).

    Source sentences

    Summary
    Intraparaventricular nuclear (iPVN) injection of [Nle(4),D-Phe(7)]-alpha-MSH (NDP-MSH) (a long-acting alpha-MSH analogue) increased plasma adrenocorticotropic hormone (ACTH) (10 min post-injection: 25.0 +/- 3.9 vs. saline 10.9 +/- 2.0, p < 0.05)
    1 context sentence
    Summary · context
    We have examined the effect of alpha-MSH and Agrp on the hypothalamo-pituitary-adrenal (HPA) axis in vitro and in vivo in male rats.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In male rats, intraparaventricular NDP-MSH increased plasma corticosterone 10 min after injection versus saline.

    In plain wordsIn male rats, NDP-MSH injected into the brain raised blood corticosterone levels compared with saline.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    IncreasePlasma corticosterone 10 min after injection
    Study

    ratn: not reported in source

    in vivo, male rats
    Comparator
    Saline
    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    Dose not stated · intraparaventricular nuclear injectionAs given in this study (rat).

    Source sentences

    Summary
    Intraparaventricular nuclear (iPVN) injection of [Nle(4),D-Phe(7)]-alpha-MSH (NDP-MSH) (a long-acting alpha-MSH analogue) increased plasma adrenocorticotropic hormone (ACTH) (10 min post-injection: 25.0 +/- 3.9 vs. saline 10.9 +/- 2.0, p < 0.05) and plasma corticosterone (10 min post-injection: 174.…
    1 context sentence
    Summary · context
    We have examined the effect of alpha-MSH and Agrp on the hypothalamo-pituitary-adrenal (HPA) axis in vitro and in vivo in male rats.

Studies that did not test the peptide alone2

In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan I (afamelanotide).

  1. 03AnimalNot a test of Melanotan I (afamelanotide) aloneAnimal study (in vivo)Efficacy outcome

    In male rats, intraparaventricular NDP-MSH combined with Agrp(83-132) increased plasma ACTH versus saline, with no additive effect.

    In plain wordsIn male rats, NDP-MSH given together with Agrp raised blood ACTH compared with saline, with no extra effect from the combination.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    IncreasePlasma ACTH after NDP-MSH plus Agrp(83-132)
    Study

    ratn: not reported in source

    in vivo, male rats
    Comparator
    Saline
    Outcome group
    Stress hormones · Endocrine and hormones

    Source sentences

    Summary
    The combination of NDP-MSH and Agrp(83-132) administered iPVN significantly increased plasma ACTH (10 min post-injection: 21.3 +/- 3.8 vs. 10.9 +/- 2.0, p < 0.05) and plasma corticosterone (10 min post-injection: 169.0 +/- 15.1 vs. saline 124.7 +/- 16.3 ng/ml, p < 0.05), but there was no additive effect.
    1 context sentence
    Summary · context
    We have examined the effect of alpha-MSH and Agrp on the hypothalamo-pituitary-adrenal (HPA) axis in vitro and in vivo in male rats.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

  2. 04AnimalNot a test of Melanotan I (afamelanotide) aloneAnimal study (in vivo)Efficacy outcome

    In male rats, intraparaventricular NDP-MSH combined with Agrp(83-132) increased plasma corticosterone versus saline, with no additive effect.

    In plain wordsIn male rats, NDP-MSH given together with Agrp raised blood corticosterone compared with saline, with no extra effect from the combination.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    IncreasePlasma corticosterone after NDP-MSH plus Agrp(83-132)
    Study

    ratn: not reported in source

    in vivo, male rats
    Comparator
    Saline
    Outcome group
    Stress hormones · Endocrine and hormones

    Source sentences

    Summary
    The combination of NDP-MSH and Agrp(83-132) administered iPVN significantly increased plasma ACTH (10 min post-injection: 21.3 +/- 3.8 vs. 10.9 +/- 2.0, p < 0.05) and plasma corticosterone (10 min post-injection: 169.0 +/- 15.1 vs. saline 124.7 +/- 16.3 ng/ml, p < 0.05), but there was no additive effect.
    1 context sentence
    Summary · context
    We have examined the effect of alpha-MSH and Agrp on the hypothalamo-pituitary-adrenal (HPA) axis in vitro and in vivo in male rats.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.